Topotecan has 8 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Carboplatin, Cisplatin, G-Csf. Patients taking Topotecan should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 8
- Major
- 4
- Moderate
- 4
Major (4)
- Topotecan + Carboplatin— Combination causes greater myelosuppression than topotecan alone with sequence-dependent interaction. Dose reduction of …
- Topotecan + Cisplatin— Combination causes severe myelosuppression with sequence-dependent interaction. At 1.25 mg/m² topotecan with 50 mg/m² ci…
- Topotecan + G-Csf— Concomitant administration can prolong the duration of neutropenia. Do not initiate G-CSF until day 6 of topotecan thera…
- Topotecan + Sofosbuvir, Velpatasvir, And Voxilaprevir— BCRP substrate whose exposure may be altered by velpatasvir and voxilaprevir inhibition. Coadministration is not recomme…
Moderate (4)
- Topotecan + Eltrombopag— BCRP substrate; eltrombopag may increase exposure. Monitor closely for signs of excessive exposure.
- Topotecan + Eltrombopag Olamine— BCRP substrate; monitor for excessive exposure and consider dose reduction if appropriate.
- Topotecan + Rolapitant— Increased plasma concentrations may result in potential adverse reactions. Monitor for adverse reactions if use cannot b…
- Topotecan + Tedizolid Phosphate— Tedizolid inhibits BCRP, increasing plasma concentrations of orally administered topotecan. Monitor for adverse reaction…